The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Investigating the efficacy of twice weekly ixazomib plus pom-dex in R/R multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, outlines findings of a Phase I/II study of twice weekly ixazomib plus pomalidomide and dexamethasone (pom-dex) in patients with relapsed/refractory (R/R) multiple myeloma (MM) (NCT04094961). Overall, results demonstrated that the regimen was well tolerated and elicited an encouraging and durable response rate in this higher-risk patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
